Clinical -patient studies

Journal of Neuro-Oncology

, Volume 88, Issue 1, pp 43-50

First online:

The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma

  • David J. SherAffiliated withHarvard Radiation Oncology Program
  • , John W. HensonAffiliated withPappas Center for Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School
  • , Bindu AvutuAffiliated withWright State University Boonshoft School of Medicine
  • , Fred H. HochbergAffiliated withPappas Center for Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School
  • , Tracy T. BatchelorAffiliated withPappas Center for Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School
  • , Robert L. MartuzaAffiliated withDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School
  • , Fred G. BarkerIIAffiliated withDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School
  • , Jay S. LoefflerAffiliated withDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School
  • , Arnab ChakravartiAffiliated withDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Purpose Temozolomide (TMZ), given concurrently with radiotherapy (RT) and as adjuvant monotherapy afterwards, has led to improved survival in glioblastoma multiforme (GBM). However, it is unclear whether its primary mechanism of action is through enhancement of radiation response, independent cytotoxicity, or both. We sought to determine the relative contribution of concomitant temozolomide in patients treated by concurrent and adjuvant TMZ versus adjuvant TMZ alone in the setting of newly diagnosed GBM. Methods and Materials We identified patients diagnosed with GBM and treated with surgery, involved-field radiotherapy, and chemotherapy at MGH between 2002 and 2004. Eligible patients received either adjuvant temozolomide alone (group 1) or temozolomide concurrently with RT followed by adjuvant TMZ (group 2). The primary endpoint of this retrospective analysis was overall survival (OS). Results Forty-three patients (group 1, n = 21; group 2, n = 22) were included in this study. The median follow-up was 33.7 months for surviving patients. There were no significant differences in baseline characteristics between these two groups. On univariate analysis, patients who received concurrent and adjuvant temozolomide experienced a 2-year OS of 51% and median survival of 25.5 months, compared with a 2-year OS of 36% and median survival of 15.6 months for group 1 patients (P < 0.05). On multivariable analysis, the hazard ratio (HR) favoring concurrent TMZ trended towards significance (HR = 0.51, P = 0.08) despite modest patient numbers. Conclusions Concurrent and adjuvant TMZ was associated with improved survival compared to adjuvant TMZ alone, highlighting the potentiation of radiation effect by temozolomide in the clinical setting.

Keywords

Combined modality therapy Glioblastoma multiforme Radiosensitization Radiotherapy Temozolomide